Neurologists' Knowledge, Practice, and Attitudes towards Pharmacovigilance and Adverse Drug Reactions Reporting Process in Epileptic Patients-Comparative Analysis from Poland and Egypt

• Published in: International journal of environmental research and public health Vol. 19; no. 7; p. 4169
• Main Authors: Kopciuch, Dorota, Kamal, Nashwa Nabil, Kamal, Nashaat Nabil, Hamdy, Nermin Aly, Paczkowska, Anna, Zaprutko, Tomasz, Ratajczak, Piotr, Fliciński, Jędrzej, Kus, Krzysztof, Nowakowska, Elżbieta
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31.03.2022; MDPI
• Subjects: Adverse Drug Reaction Reporting Systems; Comparative analysis; COVID-19; Cross-Sectional Studies; Curricula; Drug therapy; Drug-Related Side Effects and Adverse Reactions; Egypt; Epilepsy; Epilepsy - drug therapy; Health care policy; Health Knowledge, Attitudes, Practice; Humans; Knowledge; Neurologists; Pharmacology; Pharmacovigilance; Poland; Professional practice; Questionnaires; Side effects; Sociodemographics; Poland; Egypt; Arab countries; epilepsy; adverse drug reactions; Egypt; drug safety; Poland; pharmacovigilance; neurologists’ knowledge
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph19074169

To compare neurologists' knowledge, practice, and barriers of pharmacovigilance (PV) process among patients with epilepsy in Poland and Egypt. It was an international study that used an online questionnaire e-mailed to neurologists registered to practice in Poland and Egypt. Most of the neurologists were familiar with the definition of PV and adverse drug reactions (ADRs), but relatively few neurologists knew where to report ADRs, especially the Egyptian neurologists. Only 31.11% of the neurologists from Egypt and 39.90% neurologists from Poland declared that they had reported ADRs at least once during their professional practice, and few of them declared the regular reporting of such incidents. The main reason for the neurologists not reporting ADRs was the lack of time and a conviction that reporting ADRs would be an additional burden that would generate extra work. The standards of pharmacovigilance process, safety control, and quality are not the same throughout the world. System-regulated PV stabilization in a country translates into the practice of maintaining PV. Monitoring the safety of pharmacotherapy and knowledge of risks associated with ADRs should be included in the academic curricula of physician courses.